1. Phylogeny  
   Cyclin‐dependent kinase 17 (CDK17), also commonly denoted as PCTAIRE2 or PCTK2, is an evolutionarily conserved member of the cyclin‐dependent kinase superfamily. This enzyme is classified within a distinct subgroup often referred to as the PCTAIRE or “atypical” CDKs. Unlike classical cell cycle kinases that possess the conventional PSTAIRE motif, CDK17 instead bears a unique PCTAIRE motif that serves as a hallmark of its subgroup. Comprehensive sequence analysis and multiple alignment studies demonstrate that the catalytic domain of CDK17 clusters with those of other PCTAIRE kinases – most notably with CDK16 (PCTAIRE1) and CDK18 (PCTAIRE3) – forming a well‐separated clade from the typical cell cycle regulators such as CDK1, CDK2, CDK4, and CDK6 (alonso2021caracterizacióndecdk1418 pages 114-118).  
   Orthologous sequences of CDK17 have been identified in a wide range of metazoan species. This evolutionary distribution is particularly evident in organisms that possess complex, differentiated nervous systems—a distribution that has led researchers to posit that the emergence of CDK17 was concurrent with the evolution of specialized, terminally differentiated cell types. Notably, studies have documented that the full-length kinase domain of CDK17 displays high conservation in critical regions such as the HRD and DFG motifs, which underscores its retained catalytic mechanism despite divergence in other regions of the primary sequence (mikolcevic2012orphankinasesturn pages 4-6).  
   In addition, phylogenetic reconstructions have revealed that, despite some apparent functional parallels with CDK5 in neurons, CDK17 occupies an independent evolutionary branch. This branch is defined not solely by the presence of the unique PCTAIRE motif but also by distinct regulatory interactions and tissue-specific expression patterns. Investigations into invertebrate orthologs, including those reported in Drosophila, have further delineated the boundaries between canonical and atypical CDKs, thereby reinforcing the notion that the PCTAIRE subgroup represents a specialized evolutionary adaptation within the broader kinome (rascle2003l63thedrosophila pages 12-12).
2. Reaction Catalyzed  
   CDK17 operates as a serine/threonine protein kinase. As with other enzymes of the cyclin-dependent kinase family, its catalytic activity is centered on the phosphoryl transfer reaction. In biochemical terms, CDK17 catalyzes the transfer of the gamma (γ) phosphate group from adenosine triphosphate (ATP) to the hydroxyl group of serine or threonine residues present in its substrate proteins. This general reaction can be formally represented as follows:  
     ATP + [protein]-(L-serine or L-threonine) → ADP + [protein]-(L-serine/threonine)-phosphate + H⁺.  
   In vitro assays have established that histone H1 is a prototypical substrate utilized to monitor the kinase activity of CDK17, and phosphorylation of histone H1 reliably reflects the ability of CDK17 to transfer phosphate groups onto protein substrates (alonso2021caracterizacióndecdk1418 pages 29-32).
3. Cofactor Requirements  
   The catalytic function of CDK17, like that of many serine/threonine kinases, is dependent on the presence of specific divalent metal ions. In particular, magnesium ions (Mg²⁺) play an essential role as a cofactor by forming a coordination complex with ATP within the kinase active site. This complex formation is critical because the Mg²⁺ ion helps to stabilize the negative charges that emerge during the transition state of the phosphoryl transfer reaction, thus facilitating efficient catalysis. Without Mg²⁺, the correct positioning of ATP would be compromised, reducing the efficiency of phosphate transfer and thereby dampening the overall kinase activity (alonso2021caracterizacióndecdk1418 pages 32-35).
4. Substrate Specificity  
   Biochemical characterization of CDK17 has revealed that it functions as a serine/threonine kinase, and histone H1 is frequently exploited as a model substrate in experimental studies designed to probe its enzymatic activity. Although a rigorous, fully defined consensus substrate motif for CDK17 has yet to be firmly established, experimental approaches such as positional scanning peptide library assays and in vitro kinase substrate screening have provided insights into its substrate preferences. The presence of the unique PCTAIRE motif appears to contribute notably to the selection of substrates by influencing the interactions between the catalytic cleft and the target phosphorylation site on substrates. In practice, the phosphorylation of histone H1 by CDK17 is employed as an experimental readout, supporting the inference that CDK17 specifically catalyzes the addition of phosphate groups to serine/threonine residues within substrates that present a compatible local sequence context (cole2009pctkproteinsthe pages 2-4, alonso2021caracterizacióndecdk1418a pages 29-32).  
   Although finer details regarding additional substrate recognition features remain to be elucidated, the consensus emerging from these studies is that CDK17 operates through a mechanism common to many serine/threonine kinases—namely, the carefully orchestrated binding of ATP and protein substrate through conserved active site architectures and flanking regulatory regions that contribute to substrate specificity.
5. Structure  
   CDK17 is predicted to adopt the canonical bilobal structure that typifies the protein kinase superfamily. This structural arrangement comprises a relatively small N-terminal lobe that is primarily assembled from a series of β-strands and includes a key structural element known as the C-helix, as well as a larger C-terminal lobe that is predominantly helical. The interlobar cleft, situated between these two domains, forms the ATP-binding pocket and houses the catalytic machinery necessary for phosphoryl transfer.  
   Within the catalytic core, CDK17 retains several conserved motifs that are integral to its function. Notably, the HRD motif acts as a critical catalytic residue involved in the proton shuttle during phosphoryl transfer, while the DFG motif is essential for coordinating the Mg²⁺ cofactor and properly positioning ATP for the reaction. Experimental and modeling studies of related kinases such as CDK16—whose crystal structures have been more extensively characterized—suggest that CDK17’s structure would exhibit substantial similarity regarding its overall fold, catalytic residues, and active site configuration (endicott2013structuralcharacterizationof pages 3-5).  
   A distinctive structural feature of CDK17 is the presence of the PCTAIRE motif within its cyclin-binding region. This element, which diverges from the classic PSTAIRE sequence found in many cell cycle’s CDKs, serves as a defining molecular signature of the PCTAIRE kinase subgroup. While a high-resolution three-dimensional structure of CDK17 has not yet been reported in the literature, homology models based on the experimentally determined structure of CDK16 imply that CDK17 retains the typical bilobal kinase architecture. In addition to the structured kinase domain, CDK17 is predicted to possess significant N-terminal and C-terminal sequence extensions. Although these regions display lower overall sequence conservation relative to the catalytic domain, they are thought to play roles in mediating protein–protein interactions, modulating subcellular localization, and possibly contributing to the regulation of kinase activity. Furthermore, by virtue of the extension regions, additional regulatory features such as docking sites for potential interaction partners and a context-dependent influence on substrate specificity may be present (alonso2021caracterizacióndecdk1418e pages 32-35, endicott2013structuralcharacterizationof pages 3-5).  
   Additional structural elements of interest within CDK17’s catalytic core include the activation loop, a segment that in many kinases is subject to phosphorylation and undergoes conformational changes necessary for enzyme activation. In CDK17, the activation loop contains a serine residue in lieu of the conventional threonine found in several classical CDKs, a substitution that likely impacts the enzyme’s regulatory dynamics. Other critical components, such as the hydrophobic spine and the precise orientation of the αC-helix, are presumed to align closely with those observed in related kinases, collectively ensuring that the active conformation is achieved when regulatory conditions are met.
6. Regulation  
   The regulation of CDK17 centers around mechanisms that are common to many members of the cyclin-dependent kinase family while also incorporating features that are unique to the PCTAIRE subgroup. One of the primary modes of regulation is phosphorylation. In many CDKs, phosphorylation of a specific residue within the activation loop is essential for achieving full catalytic activity. In CDK17, a serine residue occupies the position at which classical cell cycle CDKs typically feature an activating threonine. Although detailed experimental studies specifically characterizing the phosphorylation dynamics of CDK17 are limited, the substitution of serine in this critical position is widely recognized as a central regulatory determinant that differentiates CDK17 from canonical kinases (alonso2021caracterizacióndecdk1418b pages 29-32).  
   Another regulatory mechanism involves the binding of a cyclin partner. In many members of the PCTAIRE family – such as CDK16 and CDK18 – cyclin Y has been identified as a critical activator that not only enhances kinase activity but also directs subcellular localization by conferring membrane-targeting properties. However, in the case of CDK17, the identity of the cyclin partner remains undefined. This absence of a clearly defined cyclin interaction has contributed to its designation as an “orphan” kinase in several studies. Despite the uncertainty over cyclin binding, cellular localization analyses have consistently demonstrated that CDK17 predominantly accumulates in the cytoplasm, with ancillary observations indicating mitochondrial association in specific cell models (alonso2021caracterizacióndecdk1418d pages 29-32, karimbayli2022dissectingtheroleb pages 19-22).  
   In addition to phosphorylation events and cyclin interactions, CDK17 is known to associate with regulatory proteins such as the Tudor Repeat Associator with PCTAIRE (Trap). Although Trap has been shown to bind CDK17, empirical evidence indicates that this interaction does not significantly modify the intrinsic kinase activity of CDK17 toward substrates like histone H1. Thus, while Trap may influence aspects of subcellular targeting or the broader assembly of signaling complexes, its binding does not equate to a direct modulation of catalytic output (alonso2021caracterizacióndecdk1418b pages 29-32).  
   Overall, the regulation of CDK17 appears to be a composite process involving phosphorylation-dependent activation, potential yet unconfirmed cyclin-mediated engagement, and compartment-specific localization cues. These regulatory mechanisms collectively influence the ability of CDK17 to participate in cellular signaling, particularly within the context of terminally differentiated neuronal cells.
7. Function  
   CDK17 is predominantly expressed in terminally differentiated, post-mitotic neurons where its selective expression markedly contrasts with that of the classical cyclin-dependent kinases active in proliferative cell types. In vitro kinase assays have demonstrated that CDK17 is capable of phosphorylating serine/threonine residues on protein substrates, with histone H1 serving as one of the canonical substrates used to monitor its activity. The phosphorylation of histone H1 by CDK17 is routinely employed as an experimental proxy for assessing its catalytic function, thereby establishing the enzyme’s role as a modulator of protein phosphorylation via reversible post-translational modification (cole2009pctkproteinsthe pages 2-4, alonso2021caracterizacióndecdk1418c pages 29-32).  
   Beyond its intrinsic kinase activity, the tissue-specific expression pattern of CDK17 implies a specialized biological role in neuronal physiology. High levels of CDK17 are observed predominantly in differentiated neuronal tissues, and multiple studies have correlated its expression with regions of the brain such as the hippocampus and olfactory bulbs. The evolutionary conservation of CDK17 in organisms possessing advanced neural architectures underscores the likelihood that CDK17 plays an essential role in sustaining the differentiated status and specialized functions of neurons (alonso2021caracterizacióndecdk1418 pages 114-118, mikolcevic2012orphankinasesturn pages 4-6).  
   In the domain of signal transduction, the catalytic activity of CDK17—specifically its ability to phosphorylate histone H1—suggests that it may be involved in the regulation of chromatin dynamics. Phosphorylation events mediated by CDK17 could influence chromatin organization and thereby modulate key processes such as transcriptional regulation or the maintenance of neuronal identity. Furthermore, its extended N-terminal and C-terminal regions, which are predicted to mediate distinct protein–protein interactions, may enable CDK17 to function as part of larger signaling complexes that integrate extracellular cues with intracellular responses in terminally differentiated neurons (rascle2003l63thedrosophila pages 12-12).  
   In addition to chromatin regulation, CDK17’s activity in phosphorylating substrates on serine/threonine residues serves to modulate other cellular processes including, but not limited to, the regulation of cell survival pathways that are particularly relevant in post-mitotic cells. The specialized regulation and expression of CDK17 within the nervous system highlight its potential contribution to maintaining neuronal function and homeostasis, especially in the context of long-term neuronal survival and the management of stress responses.
8. Other Comments  
   As one of the less extensively characterized members of the cyclin‐dependent kinase family, CDK17 occupies a unique niche in that its precise cyclin dependency and full complement of endogenous substrates have yet to be comprehensively defined. Often referred to as an “orphan” kinase, CDK17’s lack of a definitively identified cyclin partner distinguishes it from other PCTAIRE kinases such as CDK16 and CDK18, for which cyclin Y and related activators have been more thoroughly characterized. Despite this, the conservation of essential catalytic motifs—including the HRD, DFG, and notably the signature PCTAIRE amino acid sequence—strongly supports the notion that CDK17 retains the fundamental biochemical properties of a serine/threonine kinase.  
   Recent experimental findings have also drawn attention to the potential involvement of CDK17 in neurodegenerative states. For instance, elevated expression levels of CDK17 and enhanced phosphorylation events have been documented in experimental models of Alzheimer’s disease, a phenomenon that is consistent with APP-driven phosphorylation pathways. These observations, documented in recent high-quality studies, further indicate that CDK17 may assume pivotal roles in the specialized regulatory networks that underlie neural homeostasis and, in pathological contexts, neuronal degeneration (karimbayli2024insightsintothe pages 1-2).  
   Furthermore, current research endeavors are actively exploring the development of selective inhibitors that target kinases within the PCTAIRE subgroup, although the ambiguous cyclin dependency and incomplete delineation of CDK17’s regulatory network have posed challenges for the identification of highly specific inhibitory compounds. In this context, additional molecular characterization—including the elucidation of precise post-translational modifications, interaction partners, and downstream substrates—remains an important objective for ongoing studies (kamkar2015pftaire1(cyclindependent pages 49-53).  
   In summary, while CDK17’s core catalytic function as an ATP-dependent serine/threonine protein kinase has been reasonably well established, its broader regulatory dynamics, substrate repertoire, and roles in neuronal function continue to be areas of active investigation. Ongoing research is expected to provide further insights into these aspects, potentially establishing CDK17 as a significant therapeutic target in neurodegenerative and other neurological disorders.
9. References
10. alonso2021caracterizacióndecdk1418 pages 114-118
11. alonso2021caracterizacióndecdk1418 pages 29-32
12. alonso2021caracterizacióndecdk1418 pages 32-35
13. alonso2021caracterizacióndecdk1418a pages 29-32
14. alonso2021caracterizacióndecdk1418b pages 29-32
15. alonso2021caracterizacióndecdk1418c pages 29-32
16. alonso2021caracterizacióndecdk1418d pages 29-32
17. alonso2021caracterizacióndecdk1418e pages 32-35
18. cole2009pctkproteinsthe pages 2-4
19. endicott2013structuralcharacterizationof pages 3-5
20. karimbayli2022dissectingtheroleb pages 19-22
21. karimbayli2024insightsintothe pages 1-2
22. mikolcevic2012orphankinasesturn pages 4-6
23. rascle2003l63thedrosophila pages 12-12
24. shehata2012analysisofsubstrate pages 3-4
25. kamkar2015pftaire1(cyclindependent pages 49-53)

References

1. (alonso2021caracterizacióndecdk1418 pages 114-118): D Martínez Alonso. Caracterización de cdk14-18 como dianas terapéuticas en carcinoma hepatocelular. Unknown journal, 2021.
2. (alonso2021caracterizacióndecdk1418 pages 29-32): D Martínez Alonso. Caracterización de cdk14-18 como dianas terapéuticas en carcinoma hepatocelular. Unknown journal, 2021.
3. (alonso2021caracterizacióndecdk1418 pages 32-35): D Martínez Alonso. Caracterización de cdk14-18 como dianas terapéuticas en carcinoma hepatocelular. Unknown journal, 2021.
4. (alonso2021caracterizacióndecdk1418a pages 29-32): D Martínez Alonso. Caracterización de cdk14-18 como dianas terapéuticas en carcinoma hepatocelular. Unknown journal, 2021.
5. (alonso2021caracterizacióndecdk1418b pages 29-32): D Martínez Alonso. Caracterización de cdk14-18 como dianas terapéuticas en carcinoma hepatocelular. Unknown journal, 2021.
6. (alonso2021caracterizacióndecdk1418c pages 29-32): D Martínez Alonso. Caracterización de cdk14-18 como dianas terapéuticas en carcinoma hepatocelular. Unknown journal, 2021.
7. (alonso2021caracterizacióndecdk1418d pages 29-32): D Martínez Alonso. Caracterización de cdk14-18 como dianas terapéuticas en carcinoma hepatocelular. Unknown journal, 2021.
8. (alonso2021caracterizacióndecdk1418e pages 32-35): D Martínez Alonso. Caracterización de cdk14-18 como dianas terapéuticas en carcinoma hepatocelular. Unknown journal, 2021.
9. (cole2009pctkproteinsthe pages 2-4): Adam R. Cole. Pctk proteins: the forgotten brain kinases? Neurosignals, 17:288-297, Sep 2009. URL: https://doi.org/10.1159/000231895, doi:10.1159/000231895. This article has 52 citations and is from a peer-reviewed journal.
10. (karimbayli2022dissectingtheroleb pages 19-22): J Karimbayli. Dissecting the role of cdk17 in epithelial ovarian cancer. Unknown journal, 2022.
11. (karimbayli2024insightsintothe pages 1-2): Javad Karimbayli, Ilenia Pellarin, Barbara Belletti, and Gustavo Baldassarre. Insights into the structural and functional activities of forgotten kinases: pctaires cdks. Molecular Cancer, Jun 2024. URL: https://doi.org/10.1186/s12943-024-02043-6, doi:10.1186/s12943-024-02043-6. This article has 4 citations and is from a highest quality peer-reviewed journal.
12. (mikolcevic2012orphankinasesturn pages 4-6): Petra Mikolcevic, Johannes Rainer, and Stephan Geley. Orphan kinases turn eccentric. Cell Cycle, 11:3758-3768, Aug 2012. URL: https://doi.org/10.4161/cc.21592, doi:10.4161/cc.21592. This article has 66 citations and is from a peer-reviewed journal.
13. (rascle2003l63thedrosophila pages 12-12): Anne Rascle, R.Steven Stowers, Dan Garza, Jean-Antoine Lepesant, and David S. Hogness. L63, the drosophila pftaire, interacts with two novel proteins unrelated to cyclins. Mechanisms of Development, 120:617-628, May 2003. URL: https://doi.org/10.1016/s0925-4773(03)00019-4, doi:10.1016/s0925-4773(03)00019-4. This article has 14 citations.
14. (shehata2012analysisofsubstrate pages 3-4): Saifeldin N. Shehata, Roger W. Hunter, Eriko Ohta, Mark W. Peggie, Hua Jane Lou, Frank Sicheri, Elton Zeqiraj, Benjamin E. Turk, and Kei Sakamoto. Analysis of substrate specificity and cyclin y binding of pctaire-1 kinase. Cellular Signalling, 24:2085-2094, Nov 2012. URL: https://doi.org/10.1016/j.cellsig.2012.06.018, doi:10.1016/j.cellsig.2012.06.018. This article has 25 citations and is from a peer-reviewed journal.
15. (endicott2013structuralcharacterizationof pages 3-5): Jane A. Endicott and Martin E.M. Noble. Structural characterization of the cyclin-dependent protein kinase family. Biochemical Society transactions, 41 4:1008-16, Aug 2013. URL: https://doi.org/10.1042/bst20130097, doi:10.1042/bst20130097. This article has 48 citations and is from a peer-reviewed journal.
16. (kamkar2015pftaire1(cyclindependent pages 49-53): Fatemeh Kamkar. Pftaire1 (cyclin dependent kinase14): role and function in axonal outgrowth during the development of the cns. Unknown journal, 2015. URL: https://doi.org/10.20381/ruor-4143, doi:10.20381/ruor-4143. This article has 0 citations.